Compare Western Digital Corp (WDC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Western Digital Corp vs State Street SPDR S&P Biotech ETF — how do they compare? Western Digital Corp trades at $455.38 (market cap $150.95B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Western Digital Corp pays a 0.14% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Western Digital Corp nearer its low. Which is the better fit depends on your goals.
| WDC | XBI | |
|---|---|---|
Market Cap | $150.95B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $746.23 | $164.28 |
52-Week Low | $74.66 | $86.92 |
Enterprise Value | $150.42B | — |
Dividend Yield | 0.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Western Digital (WDC) trades at $454.50, up 3.74% in the last session, with a bearish technical signal but strong fundamental performance. Recent earnings beats, including Q2 2026 EPS of $3.56 versus $3.31 expected, highlight robust AI-driven storage demand. The stock is near resistance at $458, with a consensus analyst price target of $665.15 suggesting significant upside potential.
Outlook is positive due to sustained AI infrastructure growth and margin expansion, but risks include valuation concerns and competitive threats. Analyst consensus is strongly bullish with 72% buy ratings, though technical indicators signal near-term caution. Investors should weigh strong earnings momentum against potential volatility from stretched valuations.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Western Digital Corp
Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
